TWST

+ Watchlist + Portfolio

Twist Bioscience Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $142.39
52-Week Range: $23.30 – $145.51
Market Cap: $8.55B
P/E (TTM): —
EPS (TTM): -2.24
Dividend Yield: —

Advanced Metrics

Price/Book: 19.17
PEG Ratio: —
Return on Equity: -29.59%
Return on Assets: -13.09%
Gross Margin: 51.96%
Operating Margin: -30.65%
Profit Margin: -31.66%
Current Ratio: 2.67
Debt/Equity: 0.24
Total Debt: $108.59M
Free Cash Flow: $-64.82M
Revenue Growth: 23.20%
Earnings Growth: —
Enterprise Value: $8.87B

TWST Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$203.56M	$245.11M	$312.97M	$376.57M
Cost of Revenue	$119.33M	$155.38M	$179.63M	$185.57M
Gross Profit	$84.23M	$89.73M	$133.35M	$191.00M
Research & Development	$120.31M	$106.89M	$90.85M	$80.28M
Selling, General & Admin	$212.95M	$189.74M	$218.40M	$246.98M
Operating Expenses	$333.26M	$296.63M	$309.25M	$327.26M
Operating Income	-$249.02M	-$206.90M	-$175.90M	-$136.26M
EBITDA	-$211.68M	-$177.59M	-$144.47M	-$111.41M
Pretax Income	-$228.27M	-$203.47M	-$208.17M	-$76.95M
Income Tax	-$10.41M	$1.15M	$560.00K	$719.00K
Net Income	-$217.86M	-$204.62M	-$208.73M	-$77.67M
Diluted EPS	-4.04	-3.60	-3.60	-1.30
Diluted Shares	53.88M	56.88M	58.02M	59.81M

TWST Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$378.69M	$286.47M	$226.32M	$183.05M
Receivables	$40.29M	$44.06M	$34.90M	$57.02M
Inventory	$39.31M	$32.06M	$24.08M	$28.31M
Current Assets	$596.48M	$424.26M	$346.78M	$332.97M
Total Assets	$961.38M	$776.40M	$614.32M	$641.86M
Current Liabilities	$90.66M	$73.32M	$71.01M	$91.41M
Total Debt	$94.91M	$94.07M	$85.03M	$75.57M
Total Liabilities	$171.99M	$152.97M	$141.63M	$168.90M
Retained Earnings	-$828.42M	-$1.03B	-$1.24B	-$1.32B
Shareholders' Equity	$789.38M	$623.43M	$472.69M	$472.96M
Working Capital	$505.82M	$350.93M	$275.77M	$241.56M

TWST Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$124.39M	-$142.47M	-$64.09M	-$47.63M
Capital Expenditure	-$101.86M	-$27.78M	-$5.08M	-$28.00M
Free Cash Flow	-$226.24M	-$170.25M	-$69.17M	-$75.63M
Depreciation & Amortisation	$16.51M	$29.31M	$31.43M	$24.85M
Stock-Based Compensation	$79.66M	$30.28M	$50.92M	$64.46M
Investing Cash Flow	-$232.93M	$50.61M	-$3.07M	-$24.76M
Financing Cash Flow	$270.53M	$911.00K	$6.89M	$28.54M
Share Repurchases	-$7.75M	-$4.41M	-$3.98M	-$16.00K
Net Change in Cash	-$86.78M	-$90.95M	-$60.27M	-$43.85M

TWST Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$92.79M	$96.06M	$99.01M	$103.70M	$110.72M
Cost of Revenue	$46.77M	$44.76M	$48.17M	$49.73M	$53.59M
Gross Profit	$46.03M	$51.30M	$50.84M	$53.97M	$57.12M
Research & Development	$23.92M	$18.05M	$17.01M	$17.13M	$19.70M
Selling, General & Admin	$63.67M	$63.37M	$63.76M	$69.94M	$76.08M
Operating Expenses	$87.59M	$81.42M	$80.77M	$87.07M	$95.78M
Operating Income	-$41.56M	-$30.12M	-$29.93M	-$33.10M	-$38.66M
EBITDA	-$35.16M	-$24.05M	-$23.93M	-$26.91M	-$32.24M
Pretax Income	-$39.15M	$20.58M	-$26.88M	-$30.25M	-$43.98M
Income Tax	$175.00K	$191.00K	$257.00K	$253.00K	$43.00K
Net Income	-$39.33M	$20.39M	-$27.14M	-$30.51M	-$44.02M
Diluted EPS	-0.66	0.33	-0.45	-0.50	-0.71
Diluted Shares	59.65M	61.16M	60.42M	61.08M	61.70M

TWST Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$210.44M	$201.37M	$183.05M	$148.59M	$122.67M
Receivables	$49.95M	$49.85M	$57.02M	$50.06M	$87.45M
Inventory	$20.86M	$25.94M	$28.31M	$32.92M	$33.52M
Current Assets	$338.44M	$339.78M	$332.97M	$303.88M	$323.44M
Total Assets	$595.62M	$643.61M	$641.86M	$638.09M	$676.21M
Current Liabilities	$74.98M	$87.07M	$91.41M	$80.44M	$119.98M
Total Debt	$80.30M	$78.15M	$75.57M	$98.05M	$95.84M
Total Liabilities	$155.51M	$165.41M	$168.90M	$181.99M	$221.12M
Retained Earnings	-$1.31B	-$1.29B	-$1.32B	-$1.35B	-$1.39B
Shareholders' Equity	$440.11M	$478.20M	$472.96M	$456.10M	$455.09M
Working Capital	$263.47M	$252.71M	$241.56M	$223.44M	$203.46M

TWST Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$12.99M	-$1.40M	-$11.81M	-$24.81M	-$17.56M
Capital Expenditure	-$4.14M	-$9.16M	-$12.43M	-$9.97M	-$7.99M
Free Cash Flow	-$17.13M	-$10.56M	-$24.24M	-$34.79M	-$25.55M
Depreciation & Amortisation	$6.40M	$6.07M	$6.00M	$6.19M	$6.41M
Stock-Based Compensation	$20.33M	$16.06M	$16.08M	$13.27M	$18.94M
Investing Cash Flow	-$1.43M	-$9.40M	-$12.40M	-$9.93M	-$12.71M
Financing Cash Flow	$3.20M	$1.83M	$5.57M	$298.00K	$4.14M
Share Repurchases	-$5.00K	-$3.00K	-$2.00K	-$2.00K	-$8.00K
Net Change in Cash	-$11.22M	-$8.97M	-$18.64M	-$34.45M	-$26.13M

Market Snapshot

About

Twist Bioscience is a synthetic biology company that manufactures synthetic DNA using its proprietary silicon platform. The company serves customers in healthcare, agriculture, industrial chemicals, and data storage markets with custom DNA sequences for research and commercial applications.